Ocriplasmin for vitreoretinal diseases.
- Author(s): Tsui, Irena;
- Pan, Carolyn K;
- Rahimy, Ehsan;
- Schwartz, Steven D
- et al.
Published Web Locationhttps://doi.org/10.1155/2012/354979
Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.